A Phase III, Open Label, Randomized, Controlled, Multi-center Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations
|Effective start/end date||6/1/14 → 6/30/19|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.